October 2013 Tucson pulmonary journal club: tiotropium Respimat

October 2013 Tucson pulmonary journal club: tiotropium Respimat

No abstract available. Article truncated at 150 words. Tiotropium, a long-acting inhaled anticholingeric bronchodilator, is commonly used to prevent COPD exacerbations (1). Tiotropium is available as a dry powder (HandiHaler) or aqueous solution (Respimat). Direct comparisons of the two formulatio...

Full description

Bibliographic Details
Main Authors:	Eddib A, Gerald J, Berry C
Format:	Article
Language:	English
Published:	Arizona Thoracic Society 2013-11-01
Series:	Southwest Journal of Pulmonary and Critical Care
Subjects:	tiotropium Respimat Handihaler dry powder safety dysrhythmia arrthymia mortality complication myocardial infarction
Online Access:	http://www.swjpcc.com/pulmonary-journal-club/2013/11/25/october-2013-tucson-pulmonary-journal-club-tiotropium-respim.html

Similar Items

Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations
by: Tan CK, et al.
Published: (2016-09-01)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®
by: Dekhuijzen PNR, et al.
Published: (2016-08-01)

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
by: S. K. Zyryanov, et al.
Published: (2018-04-01)

Bronchodilator efficacy of 18 µg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial
by: Yildiz P, et al.
Published: (2016-11-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

Double-blind Randomized Parallel Group Study Comparing the Efficacy and Safety of Tiotropium and Ipratropium in the Treatment of COPD Patients in Taiwan
by: Jeng-Yuan Hsu, et al.
Published: (2006-01-01)

In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy
by: Ciciliani A, et al.
Published: (2017-05-01)

A rational approach to the treatment of bronchial asthma in children: what can we do to control the disease?
by: N. G. Kolosova, et al.
Published: (2020-03-01)

Dysrhythmias Induced by Streptokinase Infusion in Patients with Acute Myocardial Infarction Admitted to Cardiac Care Units in the Northwest of Iran
by: Parizad Razieh, et al.
Published: (2014-01-01)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
by: Antonio Anzueto, et al.
Published: (2020-07-01)

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
by: LaForce C, et al.
Published: (2018-06-01)

Effect of combined application of tiotropium and Salmeterol and fluticasone propionate powder on disease control in stable COPD patients
by: Xiu-Ping Han, et al.
Published: (2016-06-01)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
by: Steinmetz KO, et al.
Published: (2019-07-01)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
by: Jill A. Ohar, et al.
Published: (2020-08-01)

Role of Tiotropium as Step Up Therapy for Asthma
by: Muhammad Usman Ullah
Published: (2013-12-01)

The evolving role of tiotropium in asthma
by: McIvor ER, et al.
Published: (2017-08-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Tiotropium: a new therapeutic option in asthma
by: F. Novelli, et al.
Published: (2013-12-01)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01)

Tiotropium in COPD: clinical outcomes and economic evidence
by: Orietta Zaniolo, et al.
Published: (2010-03-01)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2017-11-01)

Efficiency of tiotropium bromide in patients with severe persistent bronchial asthma in clinical practice
by: A. F. Ivanov, et al.
Published: (2018-04-01)

Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD
by: Jõgi R, et al.
Published: (2021-04-01)

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD
by: Miravitlles M, et al.
Published: (2016-02-01)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
by: Averell CM, et al.
Published: (2019-10-01)

Dynamics of somatogenic comorbid anxiety-depressive disorders expression under the tiotropium bromide treatment influence
by: S. V. Fedosenko, et al.
Published: (2011-02-01)

Tiotropium bromide: role in the treatment of chronic obstructive pulmonary disease
by: A I Sinopalnikov
Published: (2004-03-01)

Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction
by: Toumpanakis D, et al.
Published: (2017-07-01)

Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey
by: Massimiliano Povero, et al.
Published: (2014-06-01)

Cost-effectiveness and cost-utility analysis of tiotropium treatment for Bronchiectasis: Evidence from a cross over randomised trial
by: Coomarasamy, Christin
Published: (2018)

Tiotropium: efficacy and safety in pediatric bronchial asthma
by: Natalia G. Kolosova, et al.
Published: (2021-03-01)

Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies
by: Jenkins C
Published: (2019-03-01)

Pediatric dysrhythmias
by: Meki Bilici, et al.
Published: (2015-03-01)

Tiotropium as essential maintenance therapy in COPD
by: M. Decramer
Published: (2006-12-01)

Is ‘GOLD’ standard for the management of COPD in clinical practice?
by: Barbara Yawn
Published: (2012-11-01)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
by: Zafar Zafari, et al.
Published: (2018-01-01)

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea
by: Ho Cheol Kim, et al.
Published: (2019-05-01)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
by: Tebboth A, et al.
Published: (2016-11-01)

Expression of Muscarinic Receptors and the Effect of Tiotropium Bromide in Aged Mouse Model of Chronic Asthma
by: Ji Young Kang, M.D., Ph.D., et al.
Published: (2019-01-01)

1H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide
by: Tan LC, et al.
Published: (2018-09-01)